Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of c-Myc

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 7, 2011, Pages 796-805

  Kim, Dae Young ^a   Kim, Mi Ju ^a   Kim, Hak Bong ^a   Lee, Jae Won ^a   Bae, Jae Ho ^a   Kim, Dong Wan ^b   Kang, Chi Dug ^a   Kim, Sun Hee ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Changwon National University   (South Korea)

Author keywords

C Myc; Cancer; Multidrug resistance; P gp; TRAIL

Indexed keywords

CASPASE; DEATH RECEPTOR 5; DOXORUBICIN; ETOPOSIDE; FLICE INHIBITORY PROTEIN; GLYCOPROTEIN P; MYC PROTEIN; RHODAMINE 123; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VINBLASTINE; VINCRISTINE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG SENSITIZATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION;

BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA PRIMERS; DRUG RESISTANCE, MULTIPLE; FEMALE; FLOW CYTOMETRY; HUMANS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79955601375     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.04.004     Document Type: Article

References (43)

1. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
2. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 1999, 39:361-398.
3. Zhang D., Fan D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol. 2010, 6:527-537.
4. Liu F.S. Mechanisms of chemotherapeutic drug resistance in cancer therapy-a quick review. Taiwan. J. Obstet. Gynecol. 2009, 48:239-244.
5. Lee C.H. Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR). Curr. Med. Chem. Anticancer Agents 2004, 4:43-52.
6. Lee C.H. Reversing agents for ATP-binding cassette drug transporters. Methods Mol. Biol. 2010, 596:325-340.
7. Shukla S., Wu C.P., Ambudkar S.V. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin. Drug Metab. Toxicol. 2008, 4:205-223.
8. Rowinsky E.K. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J. Clin. Oncol. 2005, 23:9394-9407.
9. Merino D., Lalaoui N., Morizot A., Solary E., Micheau O. TRAIL in cancer therapy: present and future challenges. Expert Opin. Ther. Targets 2007, 11:1299-1314.
10. Kruyt F.A. TRAIL and cancer therapy. Cancer Lett. 2008, 263:14-25.
11. Mahalingam D., Szegezdi E., Keane M., Jong S., Samali A. TRAIL receptor signalling and modulation: Are we on the right TRAIL?. Cancer Treat. Rev. 2009, 35:280-288.
12. Niemoller O., Belka C. Targeting death-receptors in radiation therapy. Results Probl. Cell Differ. 2009, 49:219-239.
13. Bevis K.S., Buchsbaum D.J., Straughn J.M. Overcoming TRAIL resistance in ovarian carcinoma. Gynecol. Oncol. 2010, 119:157-163.
14. Sumi T., Tsuneyoshi N., Nakatsuji N., Suemori H. Apoptosis and differentiation of human embryonic stem cells induced by sustained activation of c-Myc. Oncogene 2007, 26:5564-5576.
15. Albihn A., Johnsen J.I., Henriksson M.A. MYC in oncogenesis and as a target for cancer therapies. Adv. Cancer Res. 2010, 107:163-224.
16. Hoffman B., Liebermann D.A. Apoptotic signaling by c-MYC. Oncogene 2008, 27:6462-6472.
17. Nieminen A.I., Partanen J.I., Klefstrom J. c-Myc blazing a trail of death: coupling of the mitochondrial and death receptor apoptosis pathways by c-Myc. Cell Cycle 2007, 6:2464-2472.
18. Seo S.B., Hur J.G., Kim M.J., Lee J.W., Kim H.B., Bae J.H., Kim D.W., Kang C.D., Kim S.H. TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases. Mol. Cancer 2010, 9:199.
19. Ricci M.S., Jin Z., Dews M., Yu D., Thomas-Tikhonenko A., Dicker D.T., El-Deiry W.S. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol. Cell. Biol. 2004, 24:8541-8555.
20. Sheikh M.S. Myc tagging along the TRAIL to death receptor 5. Cell Cycle 2004, 3:920-922.
21. Thaker P.H., Yazici S., Nilsson M.B., Yokoi K., Tsan R.Z., He J., Kim S.J., Fidler I.J., Sood A.K. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin. Cancer Res. 2005, 11:4923-4933.
22. Gupta K.P., Ward N.E., Gravitt K.R., Bergman P.J., O'Brian C.A. Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-alpha pseudosubstrate peptide. J. Biol. Chem. 1996, 271:2102-2111.
23. Park S.J., Wu C.H., Choi M.R., Najafi F., Emami A., Safa A.R. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Biochem. Pharmacol. 2006, 72:293-307.
24. Cenni V., Maraldi N.M., Ruggeri A., Secchiero P., Del Coco R., De Pol A., Cocco L., Marmiroli S. Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase. Int. J. Oncol. 2004, 25:1599-1608.
25. Klefstrom J., Verschuren E.W., Evan G. c-Myc augments the apoptotic activity of cytosolic death receptor signaling proteins by engaging the mitochondrial apoptotic pathway. J. Biol. Chem. 2002, 277:43224-43232.
26. He Y., Zhang J., Zhang J., Yuan Y. The role of c-myc in regulating mdr1 gene expression in tumor cell line KB. Chin. Med. J. (Engl.) 2000, 113:848-851.
27. Zhong X., Safa A.R. Phosphorylation of RNA helicase A by DNA-dependent protein kinase is indispensable for expression of the MDR1 gene product P-glycoprotein in multidrug-resistant human leukemia cells. Biochemistry 2007, 46:5766-5775.
28. Yang J.K. FLIP as an anti-cancer therapeutic target. Yonsei Med. J. 2008, 49:19-27.
29. Mehta K., Devarajan E., Chen J., Multani A., Pathak S. Multidrug-resistant MCF-7 cells: an identity crisis?. J. Natl Cancer Inst. 2002, 94:1652-1654.
30. Ofir R., Seidman R., Rabinski T., Krup M., Yavelsky V., Weinstein Y., Wolfson M. Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent. Cell Death Differ. 2002, 9:636-642.
31. Nieminen A.I., Partanen J.I., Hau A., Klefstrom J. c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis. EMBO J. 2007, 26:1055-1067.
32. Mantovani I., Cappellini A., Tazzari P.L., Papa V., Cocco L., Martelli A.M. Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells. J. Cell. Physiol. 2006, 207:836-844.
33. Mizukami Y., Nonomura A., Takizawa T., Noguchi M., Michigishi T., Nakamura S., Ishizaki T. N-myc protein expression in human breast carcinoma: prognostic implications. Anticancer Res. 1995, 15:2899-2905.
34. Chrzan P., Skokowski J., Karmolinski A., Pawelczyk T. Amplification of c-myc gene and overexpression of c-Myc protein in breast cancer and adjacent non-neoplastic tissue. Clin. Biochem. 2001, 34:557-562.
35. Baker V.V., Borst M.P., Dixon D., Hatch K.D., Shingleton H.M., Miller D. c-Myc amplification in ovarian cancer. Gynecol. Oncol. 1990, 38:340-342.
36. Wu R., Lin L., Beer D.G., Ellenson L.H., Lamb B.J., Rouillard J.M., Kuick R., Hanash S., Schwartz D.R., Fearon E.R., Cho K.R. Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas. Am. J. Pathol. 2003, 162:1603-1610.
37. Kuo M.T. Roles of multidrug resistance genes in breast cancer chemoresistance. Adv. Exp. Med. Biol. 2007, 608:23-30.
38. Leonessa F., Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr. Relat. Cancer 2003, 10:43-73.
39. Blanc E., Goldschneider D., Ferrandis E., Barrois M., Le Roux G., Leonce S., Douc-Rasy S., Benard J., Raguenez G. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model. Am. J. Pathol. 2003, 163:321-331.
40. Porro A., Haber M., Diolaiti D., Iraci N., Henderson M., Gherardi S., Valli E., Munoz M.A., Xue C., Flemming C., Schwab M., Wong J.H., Marshall G.M., Della Valle G., Norris M.D., Perini G. Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells. J. Biol. Chem. 2010, 285:19532-19543.
41. Kojima H., Endo K., Moriyama H., Tanaka Y., Alnemri E.S., Slapak C.A., Teicher B., Kufe D., Datta R. Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. J. Biol. Chem. 1998, 273:16647-16650.
42. Fusi F., Saponara S., Valoti M., Dragoni S., D'Elia P., Sgaragli T., Alderighi D., Kawase M., Shah A., Motohashi N., Sgaragli G. Cancer cell permeability-glycoprotein as a target of MDR reverters: possible role of novel dihydropyridine derivatives. Curr. Drug Targets 2006, 7:949-959.
43. Nobili S., Landini I., Giglioni B., Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets 2006, 7:861-879.